Register for AllyCon 2024
Join us for a three-day experience where patients, caregivers, and advocates unite against colorectal cancer.
Biomarkers 101
Learn the basics about biomarkers and colorectal cancer, why testing is important, and what learning about your biomarker mutations can mean for your treatment options and cancer outcomes.
Biomarker type resource guide
This resource grid details the different types of biomarkers and how they relate to a colorectal cancer diagnosis and treatment.
The Alliance’s personalized treatment program
The Alliance and Perthera have partnered to provide personalized treatment options to stage III and IV patients with colorectal cancer.
If you recently had molecular/biomarker testing, your results will be analyzed with no additional testing required.
Call us at the Alliance’s Helpline at (877) 422-2030 to enroll.
Related Topics
Related reading
SidednessTop resources
Alliance supports legislation for multi-cancer early detection
Learn how the Colorectal Cancer Alliance is advocating for the passage of the Nancy Gardner Sewell Multi-Cancer Early Detection Act (HR 2407), a bipartisan bill that ensures immediate Medicare coverage for life-saving cancer detection tests once approved by the FDA.
Last updated
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Last updated
Alliance adds partners to expand 45+ Reasons campaign
The Alliance’s 45+ Reasons campaign is part of the Cycles of Impact initiative launched and supported by Independence Blue Cross in 2022 to address the urgent public health issue of colorectal cancer among the Black population.
Last updated